Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

This valuable study shows that locomotion-related modulations in the mouse visual cortex are not uniform but primarily affect neurons in muscarinic receptor-negative patches, which receive projections ...

A research team has now uncovered this mechanism. The scientists showed ... NK Cells Complexed With Bispecific Antibody Yield High Response Rates in Patients With Lymphoma Apr. 4, 2025 — A novel ...

Sep. 20, 2024 — A new study highlights the role of natural killer T cells in influencing the immune response to dengue virus, potentially reducing the severity of ... Study Identifies Areas of ...

Great news as my first paper has been published! A collaboration between Cheetham and Guimaraes labs to enhance paediatric osteosarcoma treatment with mRNA technology in CAR-NK cells: ...